These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 21888027)

  • 41. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
    Kim JE; Yoon S; Choi BR; Kim KP; Cho YH; Jung W; Kim DW; Oh S; Kim DE
    Leukemia; 2013 Aug; 27(8):1650-8. PubMed ID: 23434731
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dasatinib in chronic myelogenous leukemia.
    Chu SC; Tang JL; Li CC
    N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
    [No Abstract]   [Full Text] [Related]  

  • 44. Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.
    Iqbal Z; Aleem A; Iqbal M; Naqvi MI; Gill A; Taj AS; Qayyum A; ur-Rehman N; Khalid AM; Shah IH; Khalid M; Haq R; Khan M; Baig SM; Jamil A; Abbas MN; Absar M; Mahmood A; Rasool M; Akhtar T
    PLoS One; 2013; 8(2):e55717. PubMed ID: 23409026
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
    Roumiantsev S; Shah NP; Gorre ME; Nicoll J; Brasher BB; Sawyers CL; Van Etten RA
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10700-5. PubMed ID: 12149456
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.
    Sakai K; Ishikawa Y; Mori Y; Kobayashi M; Iriyama C; Ozawa Y; Suzuki T; Minami Y; Ishikawa K; Kaneda N; Naoe T; Kiyoi H
    Int J Hematol; 2011 Feb; 93(2):237-242. PubMed ID: 21264552
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation.
    Ferri CA; Bianchini M; Bengió RM; Moiraghi EB; Gonzalez MS; Noriega MF; Larripa IB
    Eur J Haematol; 2015 Mar; 94(3):270-2. PubMed ID: 24766374
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients.
    Qin Y; Chen S; Jiang B; Jiang Q; Jiang H; Li J; Li L; Lai Y; Liu Y; Huang X
    Ann Hematol; 2011 Jan; 90(1):47-52. PubMed ID: 20697894
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
    Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J
    Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.
    Eide CA; Adrian LT; Tyner JW; Mac Partlin M; Anderson DJ; Wise SC; Smith BD; Petillo PA; Flynn DL; Deininger MW; O'Hare T; Druker BJ
    Cancer Res; 2011 May; 71(9):3189-95. PubMed ID: 21505103
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group.
    Itonaga H; Tsushima H; Imanishi D; Hata T; Doi Y; Mori S; Sasaki D; Hasegawa H; Matsuo E; Nakashima J; Kato T; Horai M; Taguchi M; Matsuo M; Taniguchi H; Makiyama J; Sato S; Horio K; Ando K; Moriwaki Y; Sawayama Y; Ogawa D; Yamasaki R; Takasaki Y; Imaizumi Y; Taguchi J; Kawaguchi Y; Yoshida S; Joh T; Moriuchi Y; Nonaka H; Soda H; Fukushima T; Nagai K; Kamihira S; Tomonaga M; Yanagihara K; Miyazaki Y
    Leuk Res; 2014 Jan; 38(1):76-83. PubMed ID: 24262285
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
    Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
    Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.
    Swords R; Alvarado Y; Cortes J; Giles FJ
    Curr Hematol Malig Rep; 2007 May; 2(2):83-8. PubMed ID: 20425355
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
    Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
    Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
    Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
    Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance.
    Patkar N; Ghodke K; Joshi S; Chaudhary S; Mascerhenas R; Dusseja S; Mahadik S; Gaware S; Tembhare P; Gujral S; Kabre S; Kadam-Amare P; Jain H; Dangi U; Bagal B; Khattry N; Sengar M; Arora B; Narula G; Banavali S; Menon H; Subramanian PG
    Leuk Lymphoma; 2016 Nov; 57(11):2653-60. PubMed ID: 26999421
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Future Oncol; 2006 Dec; 2(6):655-65. PubMed ID: 17155893
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.
    Hayette S; Chabane K; Michallet M; Michallat E; Cony-Makhoul P; Salesse S; Maguer-Satta V; Magaud JP; Nicolini FE
    Leuk Res; 2011 Jan; 35(1):38-43. PubMed ID: 20673586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.